We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
- Authors
Dang, Chau; Lin, Nancy; Moy, Beverly; Come, Steven; Sugarman, Steven; Morris, Patrick; Abbruzzi, Alyson; Chen, Carol; Steingart, Richard; Patil, Sujata; Norton, Larry; Winer, Eric; Hudis, Clifford
- Abstract
Dose-dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel and trastuzumab (PT) is feasible. Lapatinib is effective in the treatment of human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer. We conducted a pilot study of dose-dense AC followed by PT plus lapatinib (PTL) followed by trastuzumab plus lapatinib (TL).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 18, p2982
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.26.5900